Sit Investment Associates Inc. cut its stake in Becton Dickinson and Co (NYSE:BDX) by 19.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 143,265 shares of the medical instruments supplier’s stock after selling 34,110 shares during the quarter. Sit Investment Associates Inc.’s holdings in Becton Dickinson and were worth $30,667,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the stock. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in Becton Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares during the last quarter. Harfst & Associates Inc. raised its holdings in Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares during the last quarter. Harvest Fund Management Co. Ltd raised its holdings in Becton Dickinson and by 82.8% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 338 shares during the last quarter. Acrospire Investment Management LLC raised its holdings in Becton Dickinson and by 259.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after acquiring an additional 600 shares during the last quarter. Finally, Valeo Financial Advisors LLC acquired a new stake in Becton Dickinson and in the 3rd quarter valued at about $191,000. 75.53% of the stock is currently owned by hedge funds and other institutional investors.
BDX has been the subject of a number of recent research reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 price objective on shares of Becton Dickinson and in a report on Tuesday, September 12th. Wells Fargo & Co initiated coverage on shares of Becton Dickinson and in a report on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price objective for the company. Zacks Investment Research downgraded shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Royal Bank of Canada reiterated a “hold” rating and issued a $210.00 price objective on shares of Becton Dickinson and in a report on Wednesday, October 25th. Finally, Morgan Stanley increased their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Five research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $230.20.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business’s revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.12 EPS. equities research analysts forecast that Becton Dickinson and Co will post 10.89 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were issued a dividend of $0.75 per share. The ex-dividend date was Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.32%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.73. Becton Dickinson and’s dividend payout ratio (DPR) is currently 64.52%.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/10/sit-investment-associates-inc-decreases-position-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.